End-of-day quote
Shanghai S.E.
23:00:00 26/06/2024 BST
|
5-day change
|
1st Jan Change
|
5.68
CNY
|
-5.02%
|
|
+8.19%
|
-26.61%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,102
|
2,562
|
1,459
|
2,810
|
2,311
|
2,949
|
Enterprise Value (EV)
1 |
1,979
|
2,486
|
1,404
|
2,729
|
2,178
|
2,748
|
P/E ratio
|
-2.6
x
|
74.4
x
|
-4.74
x
|
47
x
|
-66.4
x
|
226
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.01
x
|
9.78
x
|
17.3
x
|
9.99
x
|
6.61
x
|
7.98
x
|
EV / Revenue
|
4.72
x
|
9.49
x
|
16.6
x
|
9.7
x
|
6.22
x
|
7.44
x
|
EV / EBITDA
|
14.9
x
|
39.9
x
|
-7.28
x
|
70.2
x
|
-297
x
|
79
x
|
EV / FCF
|
-270
x
|
-85.6
x
|
21.7
x
|
-110
x
|
33.2
x
|
59.2
x
|
FCF Yield
|
-0.37%
|
-1.17%
|
4.61%
|
-0.91%
|
3.01%
|
1.69%
|
Price to Book
|
2.3
x
|
2.68
x
|
2.36
x
|
4.12
x
|
3.48
x
|
4.18
x
|
Nbr of stocks (in thousands)
|
400,386
|
400,386
|
375,134
|
375,134
|
376,403
|
380,951
|
Reference price
2 |
5.250
|
6.400
|
3.890
|
7.490
|
6.140
|
7.740
|
Announcement Date
|
28/04/19
|
21/04/20
|
30/03/21
|
29/03/22
|
11/04/23
|
25/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
419.2
|
262
|
84.53
|
281.4
|
349.9
|
369.3
|
EBITDA
1 |
132.8
|
62.34
|
-192.9
|
38.88
|
-7.336
|
34.79
|
EBIT
1 |
106.2
|
32.61
|
-221.9
|
14.04
|
-32.71
|
14.14
|
Operating Margin
|
25.33%
|
12.45%
|
-262.55%
|
4.99%
|
-9.35%
|
3.83%
|
Earnings before Tax (EBT)
1 |
-791.7
|
42.07
|
-315.7
|
62.18
|
-32.12
|
16.48
|
Net income
1 |
-807.9
|
34.38
|
-319.8
|
59.83
|
-34.75
|
12.97
|
Net margin
|
-192.72%
|
13.12%
|
-378.28%
|
21.26%
|
-9.93%
|
3.51%
|
EPS
2 |
-2.018
|
0.0860
|
-0.8202
|
0.1595
|
-0.0925
|
0.0342
|
Free Cash Flow
1 |
-7.335
|
-29.05
|
64.69
|
-24.76
|
65.6
|
46.43
|
FCF margin
|
-1.75%
|
-11.09%
|
76.53%
|
-8.8%
|
18.75%
|
12.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
133.48%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
357.93%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/04/19
|
21/04/20
|
30/03/21
|
29/03/22
|
11/04/23
|
25/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
123
|
76.1
|
55.6
|
80.6
|
133
|
200
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-7.33
|
-29.1
|
64.7
|
-24.8
|
65.6
|
46.4
|
ROE (net income / shareholders' equity)
|
-61.3%
|
3.6%
|
-40.5%
|
9.14%
|
-5.13%
|
1.89%
|
ROA (Net income/ Total Assets)
|
4.04%
|
1.61%
|
-12.2%
|
0.9%
|
-2.06%
|
0.86%
|
Assets
1 |
-19,972
|
2,142
|
2,612
|
6,673
|
1,686
|
1,514
|
Book Value Per Share
2 |
2.280
|
2.380
|
1.650
|
1.820
|
1.770
|
1.850
|
Cash Flow per Share
2 |
0.2500
|
0.1300
|
0.1200
|
0.2300
|
0.3600
|
0.5300
|
Capex
1 |
56
|
25.8
|
3.77
|
6.04
|
2.41
|
17.2
|
Capex / Sales
|
13.37%
|
9.86%
|
4.46%
|
2.15%
|
0.69%
|
4.67%
|
Announcement Date
|
28/04/19
|
21/04/20
|
30/03/21
|
29/03/22
|
11/04/23
|
25/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -26.61% | 314M | | +16.54% | 122B | | +20.47% | 115B | | +21.40% | 26.64B | | -22.85% | 19.91B | | -17.19% | 16.32B | | -45.95% | 15.52B | | -18.92% | 15.49B | | +60.29% | 14.83B | | +2.34% | 13.67B |
Bio Therapeutic Drugs
|